Catalona W J, Oldham R K, Herberman R B, Djeu J Y, Cannon G B
J Urol. 1977 Aug;118(2):254-7. doi: 10.1016/s0022-5347(17)57962-8.
We evaluated in vitro lymphocyte-mediated cytotoxicity against the T24 transitional carcinoma cell line and a control melanoma cell line (H894) in a double-blind study involving 25 bladder cancer patients, 19 patients with non-transitional carcinoma and 9 patients with benign conditions using a tritiated proline-labeled tumor cell assay. We found selective reactivity against T24 cells in 16 per cent of bladder cancer patients, 11 per cent of patients with non-transitional cell tumors and 22 per cent of patients with benign conditions. We found no significant differences with respect to the patterns of cytotoxic reactivity among the various patient groups. The use of different methods of lymphocyte purification and different lymphocyte to target cell ratios did not enhance the degree of specificity observed. Prior exposure to alloantigens did not account for the lack of specificity.
在一项双盲研究中,我们使用氚标记的脯氨酸标记肿瘤细胞试验,评估了25例膀胱癌患者、19例非移行细胞癌患者和9例良性疾病患者对T24移行癌细胞系和对照黑色素瘤细胞系(H894)的体外淋巴细胞介导的细胞毒性。我们发现,16%的膀胱癌患者、11%的非移行细胞肿瘤患者和22%的良性疾病患者对T24细胞具有选择性反应。我们发现不同患者组之间的细胞毒性反应模式没有显著差异。使用不同的淋巴细胞纯化方法和不同的淋巴细胞与靶细胞比例并没有提高观察到的特异性程度。先前接触同种异体抗原并不能解释缺乏特异性的原因。